Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Gkb7.0
Ginkgo Biloba – Forschung
Hilft vermutlich
278 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Ginkgo Biloba scheint in 9 von 11 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1997–2026 mit einer typischen Studiengröße von 1,104 Teilnehmenden.
Basierend auf 278 Studien · 50 Meta-Analysen · 175 RCTs · 79,364 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
9geholfen2unklar· 267 weitere ohne bewertete Effektdaten
Nach Outcome
Cognitive functionBescheidener kognitiver Nutzen bei Demenz/kognitivem Abbau; kein messbarer Gedächtnisnutzen bei gesunden Erwachsenen · 12-24 weeks
Hilft wahrscheinlich225 Studien
Neuroprotection & brain agingVerbessert die zerebrale Durchblutung und antioxidative Abwehr im ZNS · 8-12 weeks
Hilft wahrscheinlich52 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung33 Studien
Heart & blood pressureVerbessert die periphere und zerebrale Durchblutung · 8-12 weeks
Focus & attentionKein messbarer Effekt auf Aufmerksamkeit oder exekutive Funktionen bei gesunden Erwachsenen · 4-6 weeks
Überwiegend Mechanismus / Beobachtung3 Studien
Inflammation
Überwiegend Mechanismus / Beobachtung3 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung3 Studien
In Zahlen
Aus 47 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
79k
typische Studie: 1104 Personen
Stärkste Designs
225
50 gepoolt, 175 randomisiert
Zeigte Nutzen
82%
9/11 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
1
3+ Monate
3
Untersuchte Populationen
Patients with tinnitus3
Patients with dementia3
Patients with mild dementia1
Children and adolescents with ADHD1
Stetige Forschung
71 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
199720112026
1Cognitive function in mild dementiaMeta-Analysen=782 · large study2025
Einfach gesagt: The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
Riepe M et al. · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2025)
The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
Einfach gesagt: In this network meta-analysis of studies of patients with AD and a follow-up period of at least 1 year, EGb 120 mg demonstrated cognitive benefits, while placebo posed the least harm for AD.
Deng X et al. · Medicine (2024)
The network meta-analysis resulted indicated that placebo demonstrated greater effectiveness compared to Atorvastatin-calcium 80 mg (mean different [MD] = -6.93, confidence interval [CI] -11.57, -2.29) and Rivastigmine 12 mg (MD = -3.33, CI -6.56, -0.09).
In this network meta-analysis of studies of patients with AD and a follow-up period of at least 1 year, EGb 120 mg demonstrated cognitive benefits, while placebo posed the least harm for AD.
More RCTs are required to address the uncertainty surrounding the efficacy of medication.
3ADHD symptom improvement with antioxidantsMeta-Analysen=3,650 · very large study2024
Einfach gesagt: The rankings of safety and efficacy of the 12 antioxidants vary.
Zhou P et al. · PloS one (2024)
The rankings of safety and efficacy of the 12 antioxidants vary.
Due to the low methodological quality of the included studies, the probability ranking cannot fully explain the clinical efficacy, and the results need to be interpreted with caution.
More high-quality studies are still needed to verify our findings.
5Health-related quality of life (Glasgow Health Status Inventory)Systematische Übersichtn=1,915 · large study2022
Einfach gesagt: There is uncertainty about the benefits and harms of Ginkgo biloba for the treatment of tinnitus when compared to placebo.
Sereda M et al. · The Cochrane database of systematic reviews (2022)
Kein klarer Effekt
← SchlechterKein EffektBesser →
One study found that there may be little to no difference between the effects of Ginkgo biloba and placebo on health-related quality of life measured with the Glasgow Health Status Inventory at three months (MD -0.58 (scale 0 to 100), 95% CI -4.67 to 3.51; 1 study; 60 participants) (low-certainty).
Ginkgo biloba may not increase the frequency of other adverse effects (gastrointestinal upset, headache, allergic reaction) at three months compared to placebo (risk ratio 0.91, 95% CI 0.52 to 1.60; 4 studies; 1175 participants) (low-certainty).
There is uncertainty about the benefits and harms of Ginkgo biloba for the treatment of tinnitus when compared to placebo.
6Serum CRP reductionMeta-Analysen=1,104 · large study2022
Einfach gesagt: Therefore, this medicinal herb might be a possible strategy for inflammation control.
Mousavi SN et al. · Phytotherapy research : PTR (2022)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
In the meta-analysis, the weighted mean differences (WMD) in change for serum CRP were -1.5 mg/L (95% CI: -2.16, -0.85, p < 0.001).
Moreover, WMD for serum IL-6 and TNF-α were in favor of the GBLE compared to the placebo [(-16.86 pg/mL, 95% CI: -19.38, -14.34, p < 0.001); and (-4.19 pg/mL, 95%CI: -5.14, -3.23, p < 0.001), respectively].
Subgroup analysis showed that GBLE has a beneficial effect on serum CRP at the baseline levels≥3 mg/L and doses<500 mg/day.
7Cognition, function, behavior, and global changeMeta-Analysen=2,561 · very large study2015
Einfach gesagt: EGb761 at 240 mg/day is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms.
Tan MS et al. · Journal of Alzheimer's disease : JAD (2015)
EGb761 at 240 mg/day is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms.
9Repigmentation in vitiligoMeta-Analysen=4,512 · very large study2015
Einfach gesagt: This review has found some evidence from individual studies to support existing therapies for vitiligo, but the usefulness of the findings is limited by the different designs and outcome measurements and lack of quality of life measures.
Whitton ME et al. · The Cochrane database of systematic reviews (2015)
All of the studies assessed repigmentation, however only five reported on all of our three primary outcomes which were quality of life, > 75% repigmentation and adverse effects.
This review has found some evidence from individual studies to support existing therapies for vitiligo, but the usefulness of the findings is limited by the different designs and outcome measurements and lack of quality of life measures.
There is a need for follow-up studies to assess permanence of repigmentation as well as high- quality randomised trials using standardised measures and which also address quality of life.
10Tardive dyskinesia symptom reliefMeta-Analysen=1,278 · large study2018
Einfach gesagt: This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia.
Soares-Weiser K et al. · The Cochrane database of systematic reviews (2018)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Studies were primarily of short (three to six6 weeks) duration with small samples size (10 to 157 participants), and most (61%) were published more than 20 years ago.
Two studies found moderate-quality evidence of a benefit of the intervention compared with placebo: valbenazine (RR 0.63, 95% CI 0.46 to 0.86, 1 RCT, n = 92) and extract of Ginkgo biloba (RR 0.88, 95% CI 0.81 to 0.96, 1 RCT, n = 157), respectively.
This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia.